Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome

Current Gastroenterology Reports

Volumn 7, Issue 2, 2005, Pages 114-121

  Gibril, Fathia ^a   Jensen, Robert T ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CISPLATIN; DACARBAZINE; DOXORUBICIN; FLUOROURACIL; INDIUM 111; LUTETIUM; OCTREOTIDE; STREPTOZOCIN; YTTRIUM 90;

CHEMOEMBOLIZATION; CLINICAL STUDY; DIAGNOSTIC IMAGING; DUODENUM; GASTRINOMA; HUMAN; INTESTINE SURGERY; LIVER METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA; PANCREAS; PANCREAS ISLET CELL TUMOR; PATHOGENESIS; PRACTICE GUIDELINE; REVIEW; SIDE EFFECT; SURVIVAL; SYMPTOMATOLOGY; TUMOR LOCALIZATION; ZOLLINGER ELLISON SYNDROME;

EID: 20444428675     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-005-0049-2     Document Type: Review

References (67)

1. Roy P, Venzon DJ, Shojamanesh H, et al.: Zollinger-Ellison syndrome: clinical presentation in 261 patients. Medicine 2000, 79:379-411.
2. Gibril F, Jensen RT: Zollinger-Ellison syndrome revisited: diagnosis, biological markers, associated inherited disorders, and acid hypersecretion (management and consequences). Curr Gastroenterol Rep 2004, 6:454-463.
3. Jensen RT: Gastrin-producing tumors. Cancer Treat Res 1997, 89:293-334.
4. Rehfeld JF, van Solinge WW: The tumor biology of gastrin and cholecystokinin. Adv Cancer Res 1994, 63:295-347.
5. Thom AK, Norton JA, Axiotis CA, Jensen RT. Location, incidence and malignant potential of duodenal gastrinomas. Surgery 1991, 110:1086-1093.
6. Jensen RT: Zollinger-Ellison syndrome. In Surgical Endocrinology: Clinical Syndromes. Edited by Doherty GM, Skogseid B. Philadelphia: Lippincott Williams & Wilkins; 2001:291-344.
7. Norton JA, Jensen RT: Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004, 240:757-773.
8. Norton JA, Alexander HA, Fraker DL, et al.: Possible primary lymph node gastrinomas: occurrence, natural history and predictive factors: a prospective study. Ann Surg 2003, 237:650-659.
9. Arnold WS, Fraker DL, Alexander HP, et al.: Apparent lymph node primary gastrinoma. Surgery 1994, 116:1123-1130.
10. Norton JA, Fraker DL, Alexander HR, et al.: Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999, 341:635-644.
11. Gibril F, Curtis LT, Termanini B, et al.: Primary cardiac gastrinoma causing Zollinger-Ellison syndrome. Gastroenterology 1997, 112:567-574.
12. Noda S, Norton JA, Jensen RT, Gay WA, Jr: Surgical resection of intracardiac gastrinoma. Ann Thorac Surg 1999, 67:532-533.
13. Abou-Saif A, Lei J, McDonald TJ, et al.: A new cause of Zollinger-Ellison syndrome: non-small cell lung cancer. Gastroenterology 2001, 120:1271-1278.
14. Weber HC, Venzon DJ, Lin JT, et al.: Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995, 108:1637-1649.
15. Jensen RT, Gardner JD: Gastrinoma. In The Pancreas: Biology, Pathobiology and Disease. Edited by Go VLW, DiMagno EP, Gardner JD, et al. New York: Raven Press; 1993:931-978.
16. Norton JA, Jensen RT: Current surgical management of Zollinger-Ellison syndrome (ZES) in patients without multiple endocrine neoplasia-type 1 (MEN1). Surg Oncol 2003, 12:145-151.
17. Jensen RT: Natural history of digestive endocrine tumors. In Recent Advances in Pathophysiology and Management of Inflammatory Bowel Diseases and Digestive Endocrine Tumors. Edited by Mignon M, Colombel JF. Paris: John Libbey Eurotext; 1999:192-219.
18. Corleto VD, Delle Fave G, Jensen RT: Molecular insights into gastrointestinal neuroendocrine tumors: importance and recent advances. Dig Liver Dis 2002, 34:668-680.
19. Sutliff VE, Doppman JL, Gibril F, et al.: Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997, 15:2420-2431.
20. Gibril F, Doppman JL, Reynolds JC, et al.: Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and MRI in their detection, their frequency, location and effect of their detection on management. J Clin Oncol 1998, 16:1040-1053.
21. Gibril F, Venzon DJ, Ojeaburu JV, et al.: Prospective study of the natural history of gastrinoma in patients with MEN1: definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 2001, 86:5282-5293.
22. Berger AC, Gibril F, Venzon DJ, et al.: Prognostic value of initial fasting serum gastrin level in patients with Zollinger-Ellison syndrome. J Clin Oncol 2001, 19:3051-3057.
23. Metz DC, Kuchnio M, Fraker DL, et al.: Flow cytometry and Zollinger-Ellison syndrome: relationship to clinical course. Gastroenterology 1993, 105:799-813.
24. Goebel SU, Iwamoto M, Raffeld M, et al.: HER-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness. Cancer Res 2002, 62:3702-3710.
25. Chen Y-J, Zortmeyer A, Zhuang ZP, et al.: Chromosome X loss of heterozygosity frequently occurs in gastrinomas and is correlated with aggressive tumor growth. Cancer 2004, 100:1379-1387.
26. Chen Y-J, Vortmeyer A, Zhuang ZP, et al.: Loss of heterozygosity of chromosome 1q in gastrinomas: occurrence and prognostic significance. Cancer Res 2003, 63:817-823.
27. Guo SS, Wu AY, Sawicki MP: Deletion of chromosome 1, but not mutation of MEN-1, predicts prognosis in sporadic pancreatic endocrine tumors. World J Surg 2002, 26:843-847.
28. Peghini PL, Iwamoto M, Raffeld M, et al.: Overexpression of epidermal growth factor and hepatocyte growth factor receptors in a proportion of gastrinomas correlates with aggressive growth and lower curability. Clin Cancer Res 2002, 8:2273-2285.
29. Mignon M: Natural history of neuroendocrine enteropancreatic tumors. Digestion 2000, 62:51-58.
30. Lebtahi R, Cadiot G, Delahaye N, et al.: Detection of bone metastases in patients with endocrine gastroenteropancreatic tumors: bone scintigraphy compared with somatostatin receptor scintigraphy. J Nucl Med 1999, 40:1602-1608.
31. Yu F, Venzon DJ, Serrano J, et al.: Prospective study of the clinical course, prognostic factors and survival in patients with longstanding Zollinger-Ellison syndrome. J Clin Oncol 1999, 17:615-630.
32. Goebel SU, Heppner C, Burns AD, et al.: Genotype/phenotype correlations of MEN1 gene mutations in sporadic gastrinoma. J Clin Endocrinol Metab 2000, 85:116-123.
33. Serrano J, Goebel SU, Peghini PL, et al.: Alterations in the p16 INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 2000, 85:4146-4156.
34. Muscarella P, Melvin WS, Fisher WE, et al.: Genetic alterations in gastrinomas and nonfunctioning pancreatic neuroendocrine tumors: an analysis of p16/MTS1 tumor suppressor gene inactivation. Cancer Res 1998, 58:237-240.
35. Gibril F, Jensen RT: Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 2004, 36:S106-S120.
36. Gibril F, Reynolds JC, Doppman JL, et al.: Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas: a prospective study. Ann Intern Med 1996, 125:26-34.
37. Norton JA, Alexander HR, Fraker DL, et al.: Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001, 234:495-506.
38. Norton JA, Kirlen MA, Li M, et al.: Morbidity and mortality of aggressive resections in patients with advanced neuroendocrine tumors. Arch Surg 2003, 138:859-866.
39. Maton PN, Miller DL, Doppman JL, et al.: Role of selective angiography in the management of Zollinger-Ellison syndrome. Gastroenterology 1987, 92:913-918.
40. Wank SA, Doppman JL, Miller DL, et al.: Prospective study of the ability of computerized axial tomography to localize gastrinomas in patients with Zollinger-Ellison syndrome. Gastroenterology 1987, 92:905-912.
41. Orbuch M, Doppman JL, Strader DB, et al.: imaging for pancreatic endocrine tumor localization: recent advances. In Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Edited by Mignon M, Jensen RT. Basel, Switzerland: S. Karger; 1995:268-281.
42. Gibril F, Reynolds JC, Chen CC, et al.: Specificity of somatostatin receptor scintigraphy: a prospective study and the effects of false positive localizations on management in patients with gastrinomas. J Nucl Med 1999, 40:539-553.
43. Kwekkeboom D, Krenning EP, deJong M: Peptide receptor imaging and therapy. J Nucl Med 2000, 41:1704-1713.
44. Jensen RT: Peptide therapy: recent advances in the use of somatostatin and other peptide receptor agonists and antagonists. In Current Clinical Topics in Gastrointestinal Pharmacology. Edited by Lewis JH, Dubois A. Malden, MA: Blackwell Science; 1997:144-223.
45. Lebtahi R, Cadiot G, Sarda L, et al.: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 1997, 38:853-858.
46. Termanini B, Gibril F, Reynolds JC, et al.: Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology 1997, 112:335-347.
47. Strader DB, Doppman JL, Orbuch M, et al.: Functional localization of pancreatic endocrine tumors. In Endocrine Tumors of the Pancreas: Recent Advances in Research and Management. Series: Frontiers of Gastrointestinal Research. Edited by Mignon M, Jensen RT. Basel, Switzerland: S Karger; 1995:282-297.
48. Gibril F, Schumann M, Pace A, Jensen RT: Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 patients from the literature. Medicine 2004, 83:43-83.
49. Norton JA, Alexander HR, Fraker DL, et al.: Does the use of routine duodenotomy (DUODX) affect rate of cure, development of liver metastases or survival in patients with Zollinger-Ellison syndrome (ZES)? Ann Surg 2004, 239:617-626.
50. Norton JA, Doherty GD, Fraker DL, et al.: Surgical treatment of localized gastrinoma within the liver: a prospective study. Surgery 1998, 124:1145-1152.
51. Sarmiento JM, Que FG: Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin North Am 2003, 12:231-242.
52. Norton JA, Jensen RT: Unresolved surgical issues in the management of patients with the Zollinger-Ellison syndrome. World J Surg 1991, 15:151-159.
53. Sheppard BC, Norton JA, Doppman JL, et al.: Management of islet cell tumors in patients with multiple endocrine neoplasia: a prospective study. Surgery 1989, 106:1108-1117.
54. MacFarlane MP, Fraker DL, Alexander HR, et al.: A prospective study of surgical resection of duodenal and pancreatic gastrinomas in multiple endocrine neoplasia-type 1. Surgery 1995, 118:973-980.
55. Jensen RT: Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998, 243:477-488.
56. Cadiot G, Vuagnat A, Doukhan I, et al.: Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Gastroenterology 1999, 116:286-293.
57. Shojamanesh H, Gibril F, Louie A, et al.: Prospective study of the anti-tumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinomas. Cancer 2002, 94:331-343.
58. Arnold R, Wied M, Behr TH: Somatostatin analogues in the treatment of endocrine tumours of the gastrointestinal tract. Expert Opin Pharmacother 2002, 3:643-656.
59. Alexander RA, Jensen RT: Pancreatic endocrine tumors. In Cancer: Principles and Practice of Oncology. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: Lippincott Williams & Wilkins; 2001:1788-1813.
60. Faiss S, Pape UF, Bohmig M, et al.: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003, 21:2689-2696.
61. Metz DC, Jensen RT: Endocrine tumors of the gastrointestinal tract and pancreas. In Gastrointestinal Cancers. Edited by Rustgi AK. New York: WB Saunders; 2003:681-720.
62. de Jong M, Valkema R, Jamar F, et al.: Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002, 32:133-140.
63. Kwekkeboom DJ, Krenning EP: Somatostatin receptor imaging. Semin Nucl Med 2002, 32:84-91.
64. Valkema R, de Jong M, Bakker WH, et al.: Phase I study of peptide receptor radionuclide therapy with [In-DTPA] octreotide: the Rotterdam experience. Semin Nucl Med 2002, 32:110-122.
65. Kwekkeboom DJ, Bakker WH, Kam BL, et al.: Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2003, 30:417-422.
66. Lehnert T: Liver transplantation for metastatic neuroendocrine carcinoma. Transplantation 1998, 66:1307-1312.
67. Yu F, Jensen RT, Lubensky IA, et al.: Survey of genetic alterations in gastrinomas. Cancer Res 2000, 60:5536-5542.